Inventiva Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Inventiva wird ein Gewinn- und Umsatzwachstum von 17.1% bzw. 49.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 31.1% pro Jahr wachsen soll.

Wichtige Informationen

18.0%

Wachstumsrate der Gewinne

33.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	49.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Feb 22

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Sep 21

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Jan 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:IVA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	23	-108	-72	-61	6
12/31/2025	13	-95	-66	-86	8
12/31/2024	2	-106	-90	-131	5
12/31/2023	23	-110	-82	-82	N/A
9/30/2023	23	-95	-73	-73	N/A
6/30/2023	22	-80	-64	-64	N/A
3/31/2023	20	-67	-55	-54	N/A
12/31/2022	19	-54	-45	-45	N/A
9/30/2022	14	-55	-50	-49	N/A
6/30/2022	10	-56	-55	-54	N/A
3/31/2022	10	-56	-54	-53	N/A
12/31/2021	9	-50	-48	-48	N/A
9/30/2021	7	-45	-46	-45	N/A
6/30/2021	6	-41	-44	-43	N/A
3/31/2021	5	-36	-35	-35	N/A
12/31/2020	5	-34	-31	-31	N/A
9/30/2020	7	-29	-24	-24	N/A
6/30/2020	10	-25	-17	-17	N/A
3/31/2020	10	-27	-23	-23	N/A
12/31/2019	11	-30	-29	-28	N/A
9/30/2019	9	-34	-33	-33	N/A
6/30/2019	7	-37	-38	-38	N/A
3/31/2019	8	-35	-36	-35	N/A
12/31/2018	7	-33	-35	-34	N/A
9/30/2018	8	-29	-28	-27	N/A
6/30/2018	9	-25	-21	-21	N/A
3/31/2018	9	-22	-19	-19	N/A
12/31/2017	10	-19	-17	-17	N/A
9/30/2017	11	-16	N/A	-18	N/A
6/30/2017	13	-13	N/A	-19	N/A
3/31/2017	14	-10	N/A	-17	N/A
12/31/2016	14	-7	N/A	-15	N/A
9/30/2016	13	-8	N/A	-14	N/A
6/30/2016	12	-8	N/A	-13	N/A
3/31/2016	10	-9	N/A	-13	N/A
12/31/2015	9	-9	N/A	-14	N/A
12/31/2014	6	-7	N/A	-15	N/A
12/31/2013	5	-7	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IVADie Einnahmen des Unternehmens (49.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: IVADie Einnahmen des Unternehmens (49.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IVA in 3 Jahren voraussichtlich hoch sein wird

Inventiva Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken